In this Book

buy this book Buy This Book in Print
summary
The second half of the twentieth century witnessed the emergence of a new model of chronic disease—diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop—that arose in concert with a set of safe, effective, and highly marketable prescription drugs. In Prescribing by Numbers, physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. Prescribing by Numbers highlights the complex historical role of pharmaceuticals in the transformation of disease categories. Greene narrates the expanding definition of the three principal cardiovascular risk factors—hypertension, diabetes, and high cholesterol—each intersecting with the career of a particular pharmaceutical agent. Drawing on documents from corporate archives and contemporary pharmaceutical marketing literature in concert with the clinical literature and the records of researchers, clinicians, and public health advocates, Greene produces a fascinating account of the expansion of the pharmaceutical treatment of chronic disease over the past fifty years. While acknowledging the influence of pharmaceutical marketing on physicians, Greene avoids demonizing drug companies. Rather, his provocative and comprehensive analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical analysis can help to address the problems inherent in the program of pharmaceutical prevention.

Table of Contents

  1. Cover
  2. restricted access Download |
  1. Frontmatter
  2. restricted access Download |
  1. Contents
  2. restricted access Download |
  1. Preface
  2. pp. vii-xi
  3. restricted access Download |
  1. Acknowledgments
  2. pp. xiii-xv
  3. restricted access Download |
  1. Introduction. The Pharmacopoeia of Risk Reduction
  2. pp. 1-17
  3. restricted access Download |
  1. PART ONE: Diuril and Hypertension, 1957–1977
  2. pp. 19-20
  1. 1. Releasing the Flood Waters: The Development and Promotion of Diuril
  2. pp. 21-50
  3. restricted access Download |
  1. 2. Shrinking the Symptom, Growing the Disease: Hypertension after Diuril
  2. pp. 51-79
  3. restricted access Download |
  1. PART TWO: Orinase and Diabetes, 1960–1980
  2. p. 81
  1. 3. Finding the Hidden Diabetic: Orinase Creates a New Market
  2. pp. 83-114
  3. restricted access Download |
  1. 4. Risk and the Symptom: The Trials of Orinase
  2. pp. 115-147
  3. restricted access Download |
  1. PART THREE: Mevacor and Cholesterol, 1970–2000
  2. p. 149
  1. 5. The Fall and Rise of a Risk Factor: Cholesterol and Its Remedies
  2. pp. 151-188
  3. restricted access Download |
  1. 6. Know Your Number: Cholesterol and the Threshold of Pathology
  2. pp. 189-219
  3. restricted access Download |
  1. Conclusion. The Therapeutic Transition
  2. pp. 221-240
  3. restricted access Download |
  1. Notes
  2. pp. 241-308
  3. restricted access Download |
  1. Index
  2. pp. 309-318
  3. restricted access Download |

Additional Information

ISBN
9780801892097
Related ISBN
9780801891007
MARC Record
OCLC
310115350
Pages
336
Launched on MUSE
2012-01-01
Language
English
Open Access
No
Back To Top

This website uses cookies to ensure you get the best experience on our website. Without cookies your experience may not be seamless.